Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Clinical trial NCT03989206 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03989206
- Sponsor
- Galderma R&D
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-30
- Primary completion
- 2026-08-31
- Enrollment
- 1700
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.